Know What's Happening in BioTech
Know What's Happening in BioTech
BioTech Pulse
EMAIL DIGESTS
Daily
Every morning
Weekly
Tuesday recap
EMAIL DIGESTS
Daily
Every morning
Weekly
Tuesday recap
Researchers have engineered magnetic nanocomposites cloaked in cell membranes to serve as carriers for DNA probes targeting cancer‑related microRNAs. Upon binding miRNA, duplex‑specific nuclease triggers cyclic cleavage, releasing labeled signal strands that bind to a tetrahedral DNA interface on an electrode. The resulting electrochemical response quantifies two NSCLC‑associated miRNAs simultaneously, achieving ultrahigh sensitivity and stage discrimination. The platform is regenerative, cost‑effective, and suitable for non‑invasive clinical diagnostics.
Researchers have designed a Ti‑Mo‑Hf‑Cu medium entropy alloy that spontaneously forms nanoscale acicular (Ti,Hf)2Cu precipitates. The precipitates generate localized micro‑area potential differences, delivering strong antibacterial activity while simultaneously promoting osteogenic cell growth. Additionally, the alloy’s low elastic modulus closely matches...
Monash Health and Monash University have secured a $100,000 grant from the Love Your Sister Foundation to develop a graphene‑oxide biosensor that detects circulating tumor DNA for early cancer diagnosis. The interdisciplinary team will engineer a functionalised GO surface that...
Little Étoile Mothers’ Care, launched by Max Biocare, introduces a science‑led skincare line for pregnant, breastfeeding and postpartum women. The range is formulated in a GMP‑licensed Australian facility and vetted through a proprietary “inscreen” safety protocol that screens for reproductive...
Codexis unveiled its ECO Synthesis™ Manufacturing Platform, a fully aqueous, enzymatic process for producing siRNA at scale. The platform demonstrated a 10‑gram laboratory synthesis and can deliver up to 100 grams of GLP‑grade RNA for toxicology studies, positioning it to surpass traditional...
The FDA released draft guidance endorsing measurable residual disease (MRD) negativity as a surrogate endpoint for accelerated approval in multiple myeloma. The guidance implements the unanimous 2024 recommendation from the Oncologic Drugs Advisory Committee. By formalizing MRD negativity, the agency...
After more than four years of a biotech bear market, investors are now seeing a genuine bullish turn. Lower interest rates, clearer policy signals and strengthening fundamentals are aligning to revive capital flows. BioCentury’s survey of 15 buyside investors and...
Researchers have shown that bird retinas operate in permanent oxygen deprivation, relying on anaerobic glycolysis rather than blood‑borne oxygen. Direct measurements revealed that the inner retina of species like the zebra finch is fully anoxic, overturning the long‑standing belief that...
A decade‑old, sensational headline claimed Stanford stem‑cell therapy helped a stroke patient walk, sparking false hope. The product, SB623, showed modest signals in an early open‑label study but failed to meet endpoints in a Phase 2b stroke trial, leading to its...
Researchers at Purdue University and Kiel University unveiled TreeStructor, an AI‑driven system that can isolate and reconstruct individual trees within full forest point‑cloud datasets, delivering complete 3‑D models. The approach builds a dictionary of geometric tree parts and uses neural...
European drug price negotiations for 2026 are at a crossroads, with member states and the EU Commission offering conflicting perspectives. U.S. policymakers are lobbying for tighter price alignment to curb American market spillover, while European regulators stress sovereign health budgets....
A study by CIIMAR and Portuguese universities shows natural cyclic peptides from marine cyanobacteria can be incorporated into anti‑fouling coatings, effectively delaying macrofouling without releasing toxic biocides. Laboratory and field tests demonstrated inhibition of bacterial biofilms and mussel larval settlement,...
The submission contains only navigation links and no substantive article text about the cereblon allosteric site. Consequently, no scientific details, data, or conclusions can be extracted. The request highlights the need for the full manuscript—including title, author, date, and body—to...
A recent open‑access review catalogs several endogenous metabolites—taurine, betaine, α‑ketoglutarate, oxaloacetate, hydrogen sulfide, NAD+, and methionine—that modestly extend lifespan or improve healthspan in animal models. The paper highlights how up‑regulating these compounds, or restricting methionine, can mitigate age‑related decline in...
PraxisPro, a data‑intelligence startup focused on life‑sciences, announced the close of an oversubscribed $6 million seed round on Jan 21, 2026 in Houston, Texas. The round was led by AlleyCorp and attracted participation from Flybridge, South Loop Ventures, Zeal Capital Partners, True Ventures,...
Researchers at the Max Planck Institute created a high‑content image‑based screening platform using human pancreatic progenitor organoids. Screening 538 compounds identified GSK3A/B inhibitors that activate WNT signaling, prompting acinar‑specific gene expression. By removing the growth factor FGF, the organoids self‑organized...
Researchers at Xidian University have engineered soft‑membrane nanoparticles (PGC@FM) that fuse selectively with cancer cells, exploiting the lower membrane stiffness of tumors. The particles deliver mRNA directly to the cytoplasm, bypassing lysosomal degradation that plagues conventional lipid nanoparticles. In mouse...
Scientists from CSMCRI, IIT Gandhinagar, NTU Singapore and S N Bose have created ultra‑selective crystalline membranes called POMbranes, featuring permanent 1 nm pores. The membranes achieve ten‑fold higher separation performance than conventional polymer filters while remaining flexible, chemically stable and scalable. Laboratory tests show...
The FDA released a draft guidance aimed at accelerating the development of multiple myeloma therapies by clarifying the use of surrogate endpoints and adaptive trial designs. Johnson & Johnson, which already markets several approved MM drugs, welcomed the guidance as...
Researchers at the Technical University of Denmark have engineered Chinese Hamster Ovary (CHO) cell lines that can produce the essential amino acids threonine and histidine, eliminating the need for these nutrients in culture media. The same team created a CHO...
Scientists in China have engineered Saccharomyces cerevisiae to biosynthesize the antitumor isoflavonoid medicarpin, achieving peak titers of over 157 µg/L in the GlaN26 strain. The effort required constructing 26 yeast variants and rewiring glycolysis, the pentose phosphate, shikimate, and isoflavonoid pathways....
Rapid growth of biosimilars is reshaping retinal therapeutics, with ranibizumab biosimilars already market leaders and aflibercept biosimilars poised to follow. The two drugs differ fundamentally in manufacturing: ranibizumab is produced in Escherichia coli, requiring complex refolding of inclusion bodies, while...
A recent study highlights additive manufacturing as a flexible alternative for producing bespoke bioreactors used in cell and gene therapy. Unlike traditional injection‑molded single‑use devices, 3D printing allows unlimited shape and size changes without new molds. Although per‑part costs are...
At Pharmapack 2026, ACG Packing unveiled SuperPod™, a new cold‑form blister laminate that reduces cavity size by up to 39% and triples the number of blisters per shot. The multi‑layer construction enables deeper draws without compromising the aluminum barrier, cutting material...
Johnson & Johnson downplayed the impact of the new Most‑Favored‑Nation (MFN) pricing clause on its earnings, asserting that existing contracts and a diversified portfolio cushion any downside. The company projected a robust growth trajectory through 2026, driven by its oncology...
Researchers at NUS Medicine identified the transcription factor DMTF1 as a key driver of neural stem‑cell function in the aging brain. Experiments using human‑derived and telomere‑dysfunctional stem cells showed that DMTF1 levels drop with age, and restoring its expression revives...
Tanabe Pharma announced that its oral melanocortin‑1 receptor (MC1R) agonist achieved its primary endpoint in a Phase 2 trial for a rare blood disorder, delivering a 60% response rate among patients. The pill offers a non‑injectable option that could reduce transfusion...
IntraBio announced that its experimental therapy for ataxia‑telangiectasia (A‑T) achieved statistically significant improvement in motor function in a pivotal Phase 3 trial. The study met its primary endpoint and demonstrated a favorable safety profile across a genetically defined patient cohort....
Johnson & Johnson reported a 9.1% rise in fourth‑quarter sales to $24.6 billion and projected full‑year revenue of $100‑101 billion for 2026, up from $94.2 billion. The company’s growth is driven by strong cancer and immune‑therapy sales, offsetting a steep decline in its...
University of Oxford engineers quantum‑enabled proteins, creating magneto‑sensitive fluorescent proteins (MFPs) that respond to magnetic and radio‑frequency fields when illuminated. Published in Nature, the study demonstrates deliberate design of quantum mechanical processes inside biomolecules, moving beyond observation of natural quantum...
In this episode of The Bio Report, host and guests discuss Immuto Scientific’s novel approach to drug discovery that targets disease‑specific protein conformations rather than genetic sequences. CEO Faraz Choudhury explains how the company’s AI‑driven structural surfaceomics platform maps the...
Researchers at MD Anderson and Stanford engineered bispecific nanobodies that anchor viral particles to the respiratory mucus, boosting the airway’s first‑line defense. In preclinical mouse models the nanobodies reduced infection rates for influenza and SARS‑CoV‑2 and cut viral transmission. The...
The Biotech CEO Sisterhood’s pink‑themed gathering at the J.P. Morgan Healthcare Conference drew up to 1,000 participants, underscoring a growing movement to spotlight women executives in biopharma. Since its 2022 launch, the group has expanded to about 350 members and...
Novo Nordisk announced a strategic deal to acquire Aspect Biosystems, a 3‑D bioprinting company specializing in cell‑based therapies. The acquisition aims to accelerate Novo's development of encapsulated beta‑cell products for type 1 diabetes, leveraging Aspect's platform to scale manufacturing. Financial terms...
KalVista secured FDA approval for its oral on‑demand hereditary angioedema drug Ekterly after a delayed PDUFA review and reported political pressure. The pill is positioned as the only oral option in a market dominated by injectable therapies, targeting the $3.8‑6.5 billion...
Drug makers Regeneron, Eli Lilly and Summit Therapeutics are converging on identical biological targets, intensifying competition for potential megablockbuster therapies. The firms are pursuing treatments for diseases lacking effective options, hoping to capture large market share. Their pipelines reveal overlapping...
Ziftomenib (Komzifti®), an oral menin‑KMT2A inhibitor, received FDA approval in November 2025 for adults with relapsed or refractory acute myeloid leukemia (AML) harboring NPM1 mutations. The drug blocks the menin‑KMT2A protein interaction, disrupting leukemogenic transcription programs. In the Phase 1/2 KOMET‑001...
European Commission approved Otsuka’s Dawnzera, a first‑in‑class antisense RNA therapy, for prophylaxis of hereditary angioedema in patients 12 and older. Clinical data showed an 81% attack‑rate reduction with four‑weekly dosing and up to 94% reduction after one year. Otsuka secured...
Roche, through Genentech, is boosting its North Carolina manufacturing commitment from $700 million to roughly $2 billion to expand a 700,000‑square‑foot facility in Holly Springs. The plant, slated to be operational by 2029, will add about 100 jobs, bringing total staffing to over...
GSK has committed $20 million upfront and up to $265 million in milestones to partner with South Korea’s Alteogen, aiming to create a subcutaneous version of its PD‑1 cancer drug Jemperli. Alteogen will supply its Hybrozyme recombinant hyaluronidase (ALT‑B4) to enable under‑skin...
Hopstem Biotech received FDA clearance to begin US clinical trials of its iPSC‑derived stroke therapy, hNPC01, under an accelerated development pathway. The company completed a Phase 1 study in China showing sustained motor improvements over 18 months without safety concerns. The...
Think Bioscience, a Boulder‑based biotech, announced a $55 million Series A round that was oversubscribed by investors. The capital will fund its platform that seeks previously hidden binding pockets on proteins and other molecules. By targeting these cryptic sites, the company aims...
ImmunityBio announced an FDA pathway to refile for Anktiva in papillary‑only NMIBC after an initial rejection. The IL‑15 agonist, already approved for BCG‑refractory CIS, generated $113 million in sales last year. Data from the QUILT‑3.032 trial show a 58.2% 12‑month disease‑free...
University of Calgary researchers have developed an AI‑driven early‑warning system that can predict whirling disease in trout and salmon using minimal data. By training a hidden Markov model on a single confirmed outbreak and leveraging readily available environmental metrics such...
Regular physical activity mitigates immunosenescence, restoring immune competence in older adults. Exercise improves insulin sensitivity, modulates mTOR/AMPK pathways, and reduces chronic inflammation. Metabolic remodeling, myokine release, and gut microbiota shifts enhance both innate and adaptive immunity, increasing naive T‑cell output....
Heart failure with preserved ejection fraction (HFpEF) is driven in part by stiff titin isoforms. Researchers showed that partially inhibiting the splicing regulator RBM20 with antisense oligonucleotides shifts titin expression toward more compliant N2BA‑N isoforms. In a mouse model mimicking...
At the JPMorgan Healthcare Conference, Novo Nordisk’s oral Wegovy quickly reached roughly 3,100 patients within its first week, underscoring strong demand for oral obesity therapies. Eli Lilly’s competing oral candidate, orforglipron, saw its FDA decision pushed back to April 10, despite...
What’s exciting now with autonomous labs is you can get the closer to the flexibility of the bench but automated. So you could design 200 different experiments to run overnight and read out for you in the morning. ...
1/ Your cancer prediction model has 1,000 citations, but It's never been used on a patient. "Some models are wrong, yours are useless." A Cambridge researcher analyzed why most clinical AI tools die in academic journals instead of helping people. https://t.co/mIXS32qDr3
Was great to give a seminar today to the Dept. Food Technology at @ChulalongkornU University, Bangkok 🇹🇭 I present regulary on our lab's work on engineered materials based on bacterial cellulose (BC), but I think today breaks the record for the...
